Professional paper

Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)

Lana Tambić Bukovac ; Rheumatology Department, Children's Hospital Srebrnjak, Zagreb, Croatia
Mandica Vidović ; Rheumatology Department, Children's Hospital Srebrnjak, Zagreb, Croatia
Lovro Lamot ; Rheumatology Department, Children's Hospital Srebrnjak, Zagreb, Croatia
Marija Perica ; Rheumatology Department, Children's Hospital Srebrnjak, Zagreb, Croatia
Miroslav Harjaček ; Rheumatology Department, Children's Hospital Srebrnjak, Zagreb, Croatia

Abstract

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, and one of the major causes of short-term or long-term disability, and impairment of quality of life in childhood. Without early and adequate treatment the disease will progress and result with irreparable joint damage. The choice of therapy depends on the JIA subtype, disease activity index, prognostic factors, and prooven efficacy and probable side-effects of the drugs. The goal of modern JIA therapy is the achievement of complete disease remission, and not only the improvement of symptoms and temporarily inflammation control. The implementation of biologics significantly altered therapeutic approach to children with resistant JIA. We present Croatian guidelines on biologic drugs for the treatment of patients with JIA.

Keywords

juvenile idiopathic arthritis; biologic drugs

Hrčak ID:

123601

URI

https://hrcak.srce.hr/123601

Publication date:

1.6.2013.

Article data in other languages: croatian

Visits: 3.241 *